CSD/BM/SE/2026-27
Date: 5th November, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Board of Directors of the Company, at its meeting held today i.e. November 5, 2026, has considered and approved Un-Audited Financial Results (Standalone and Consolidated) along with review reports of the Statutory Auditors for the quarter and half year ended 30th September, 2026.

Enclosed herewith the following documents: -

1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026 enclosed as **Annexure 1**
2. Limited Review Reports of Statutory Auditors of the Company enclosed as **Annexure 2**
3. News Release of the Company is enclosed as **Annexure 3**

Update on patents are available at: https://www.suven.com/Patentupdates.aspx

The Board Meeting commenced at 12:00 Noon (IST) and concluded at 1:15 PM (IST).

This is for your information and records.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Kandari Sangeetha Laxmi

Digitally signed by Kandari Sangeetha Laxmi
Date: 2026.11.05 13:21:52 +05'30'

K. Sangeetha Laxmi
Company Secretary and Compliance officer

SUVEN LIFE SCIENCES LIMITED

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500034, Telangana, India
Tel: 91 40 2354 1142/ 1152 Email: investorservices@suven.com Website: www.suven.com CIN: L24110TG1989PLC009713

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & SIX MONTHS ENDED SEPTEMBER 30, 2026

(Rs. in Lakhs, except per share data)

STANDALONE

Sl. No.	PARTICULARS	Quarter Ended			Six Months period ended		Year Ended
		30-Sep-2026	30-Jun-2026	30-Sep-2025	30-Sep-2026	30-Sep-2025	31-Mar-2026
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
1	**Income**						
	Revenue from operations	119.86	356.58	91.92	476.44	278.59	711.47
	Other Income	673.44	752.36	377.78	1,425.80	436.68	1,391.05
	Total income	**793.30**	**1,108.94**	**469.70**	**1,902.24**	**715.27**	**2,102.52**
2	**Expenses**						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	718.96	728.18	607.65	1,447.14	1,205.21	2,414.94
	d) Finance costs	45.76	47.61	-	93.37	-	15.78
	e) Depreciation and amortisation expense	230.23	215.51	131.68	445.74	268.52	561.35
	f) R & D Expenses	991.93	1,275.60	877.32	2,267.53	1,396.09	2,797.24
	g) Other Expenses	444.55	453.95	397.56	898.50	867.83	1,799.49
	Total expenses	**2,431.43**	**2,720.85**	**2,014.21**	**5,152.28**	**3,737.65**	**7,588.80**
3	**Profit before exceptional items & Tax (1-2)**	**(1,638.13)**	**(1,611.91)**	**(1,544.51)**	**(3,250.04)**	**(3,022.38)**	**(5,486.28)**
4	Exceptional Items	-	-	-	-	-	-
5	**Profit before Tax (3-4)**	**(1,638.13)**	**(1,611.91)**	**(1,544.51)**	**(3,250.04)**	**(3,022.38)**	**(5,486.28)**
6	**Tax Expenses**						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
7	**Net Profit/ (Loss) for the period/ year(5-6)**	**(1,638.13)**	**(1,611.91)**	**(1,544.51)**	**(3,250.04)**	**(3,022.38)**	**(5,486.28)**
8	**Other Comprehensive Income**						
8.a	**(i) Items that will not be reclassified to profit or loss**	**(5.54)**	**(5.55)**	**(1.50)**	**(11.09)**	**(3.00)**	**(22.19)**
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	**(i) Items that will be reclassified to profit or loss**	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	**(5.54)**	**(5.55)**	**(1.50)**	**(11.09)**	**(3.00)**	**(22.19)**
9	**Total Comprehensive Income for the period**	**(1,643.67)**	**(1,617.46)**	**(1,546.01)**	**(3,261.13)**	**(3,025.38)**	**(5,508.47)**
10	Paid-up equity share capital (Face Value of the Share Re.1.00 each)	**2,825.63**	**2,639.93**	**2,274.74**	**2,825.63**	**2,274.74**	**2,637.20**
11	Other Equity		-	-	-	-	**1,47,699.51**
12	**Earning Per Share (EPS)** (Face value of Rs.1/- each)						
	a) Basic	**(0.58)**	**(0.61)**	**(0.70)**	**(1.19)**	**(1.36)**	**(2.41)**
	b) Diluted	**(0.58)**	**(0.61)**	**(0.70)**	**(1.19)**	**(1.36)**	**(2.41)**
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

SUVEN LIFE SCIENCES LTD. HYDERABAD

(Rs. in Lakhs, except per share data)

Sl. No.	PARTICULARS	CONSOLIDATED					
		Quarter Ended			Six Months period ended		Year Ended
		30-Sep-2026	30-Jun-2026	30-Sep-2025	30-Sep-2026	30-Sep-2025	31-Mar-2026
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
1	**Income**						
	Revenue from operations	119.86	356.58	91.92	476.44	278.59	711.47
	Other Income	673.44	752.36	377.80	1,425.80	437.78	1,393.01
	Total income	**793.30**	**1,108.94**	**469.72**	**1,902.24**	**716.37**	**2,104.48**
2	**Expenses**						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	718.96	728.18	607.65	1,447.14	1,205.21	2,414.94
	d) Finance costs	45.76	47.61	-	93.37	-	15.78
	e) Depreciation and amortisation expense	230.23	215.51	131.68	445.74	268.52	561.35
	f) R & D Expenses	10,029.99	12,383.10	7,032.13	22,413.09	11,180.97	24,818.81
	g) Other Expenses	462.57	495.57	429.25	958.14	944.35	1,928.01
	Total expenses	**11,487.51**	**13,869.97**	**8,200.71**	**25,357.48**	**13,599.05**	**29,738.89**
3	**Profit before exceptional items, Tax (1-2)**	**(10,694.21)**	**(12,761.03)**	**(7,730.99)**	**(23,455.24)**	**(12,882.68)**	**(27,634.41)**
4	Exceptional Items	-	-	-	-	-	-
5	**Profit before Tax (3-4)**	**(10,694.21)**	**(12,761.03)**	**(7,730.99)**	**(23,455.24)**	**(12,882.68)**	**(27,634.41)**
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
7	**Net Profit/ (Loss) for the period/ year(5-6)**	**(10,694.21)**	**(12,761.03)**	**(7,730.99)**	**(23,455.24)**	**(12,882.68)**	**(27,634.41)**
8	**Other Comprehensive Income**						
8.a	**(i) Items that will not be reclassified to profit or loss**	**(5.54)**	**(5.55)**	**(1.50)**	**(11.09)**	**(3.00)**	**(22.19)**
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	**(i) Items that will be reclassified to profit or loss**	**(17.90)**	**1.95**	**10.02**	**(15.95)**	**6.40**	**(96.20)**
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	**(23.44)**	**(3.60)**	**8.52**	**(27.04)**	**3.40**	**(118.39)**
9	**Total Comprehensive Income for the period (7+ 8)**	**(10,717.65)**	**(12,764.63)**	**(7,722.47)**	**(23,482.28)**	**(12,879.28)**	**(27,752.80)**
10	Paid-up equity share capital (Face Value of the Share Re.1.00 each)	**2,825.63**	**2,639.93**	**2,274.74**	**2,825.63**	**2,274.74**	**2,637.20**
11	Other Equity	-	-	-	-	-	**56,502.76**
12	**Earning Per Share (EPS)** (Face value of Rs.1/- each)						
	a) Basic	**(3.77)**	**(4.84)**	**(3.48)**	**(8.61)**	**(5.80)**	**(12.13)**
	b) Diluted	**(3.77)**	**(4.84)**	**(3.48)**	**(8.61)**	**(5.80)**	**(12.13)**
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

SUVEN LIFE SCIENCES LTD. * HYDERABAD *

NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 05, 2026. The results for the quarter and six months ended September 30, 2026 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the two Wholly Owned Subsidiaries, Suven Neurosciences, Inc. and Suven Neurosciences Pte. Ltd. (which was incorporated on 14 July 2026) and has been consolidated from that date.

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5.1) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, 1,33,200 stock options were granted on May 13, 2026 by the Nomination & Remuneration Committee.

5.2) ESOP: for the quarter ended September 30, 2026, the Company has recognized an employee benefit expense (EBP) of Rs.220.96 lakhs in accordance with Ind AS 102 – Share-based Payment.

5.3) During the previous quarter ended June 30, 2026, the Company has allotted 2,71,970 equity shares of Rs.1 each, pursuant to the exercise of stock options by the employees of the company under Employee Stock Options Scheme 2020.

6) Preferential Issue: The Board of Directors of the Company has approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025.

7) During the quarter the Company has alloted 18570133 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants (allotted on 08.07.2026) to seventeen allottees, upon receipt of 100% of the warrant consideration amounting to Rs.24883.98 lakhs.

The Summary of utilization of funds so received under the Preferential Issue as on 30.09.2026:

Particulars	**Amount Rs. in Lakhs**
Funds raised through Preferential Issue	85,764.02
Less: Amount Utilised	53,763.36
Unutilized Amount	**32,000.66**

8) The figures for the current quarter and quarter ended September 30, 2025 are the balancing figures between the period ended September 30, 2026 and September 30th, 2025, respectively and published year to date figures upto 1st quarter ended 30th June 2026 and 30th June 2025, respectively, regrouped

For SUVEN LIFE SCIENCES LIMITED

SUVEN LIFE SCIENCES LTD. * HYDERABAD *

Place : Hyderabad
Date : 05 November 2026

VENKAT JASTI
Chairman & MD
DIN: 00278028

SUVEN LIFE SCIENCES LIMITED

Statement of Assets & Liabilities

Rs. in Lakhs

	Particulars	Standalone as at		Consolidated as at	
		30-Sep-2026	31-Mar-2026	30-Sep-2026	31-Mar-2026
A	ASSETS	UN AUDITED	AUDITED	UN AUDITED	AUDITED
1	**Non-current assets**				
	(a) Property,Plant and Equipment	8,988.77	5,570.33	8,988.77	5,570.33
	(b) Capital Work-in-Progress	412.78	359.60	412.78	359.60
	(c) Other Intangible Assets	13.17	14.47	13.17	14.47
	(d) Right of use Assets	2,453.24	1,714.74	2,453.24	1,714.74
	(e) Financial Assets				
	I. Investments	1,11,144.29	91,284.63	-	-
	II.Other financial assets	92.42	87.50	92.42	87.50
	(f) Other Non-current Assets	352.49	3.88	352.49	3.88
	Total Non-Current assets	**1,23,457.16**	**99,035.15**	**12,312.87**	**7,750.52**
2	**Current assets**				
	Inventories	10.63	10.20	10.63	10.20
	(a) Financial Assets				
	(i) Investments in mutual funds	1,369.77	18,065.16	1,369.77	18,065.16
	(ii) Trade Receivables	151.24	150.84	151.24	150.84
	(iii) Cash and Cash equivalents	111.60	228.13	2,412.78	827.91
	(iv) Bank balances otherthan (III) above	30,892.70	32,917.70	30,892.70	32,917.70
	(v) Other financial assets	1,395.66	370.31	1,395.66	370.31
	(b) Current Tax asset(net)	325.95	194.92	325.95	194.92
	(c) Other current assets	1,770.63	2,133.84	1,770.63	2,133.84
	Total Current assets	**36,028.18**	**54,071.10**	**38,329.36**	**54,670.88**
	TOTAL - ASSETS	**1,59,485.34**	**1,53,106.25**	**50,642.23**	**62,421.40**
B	**EQUITY AND LIABILITIES**				
1	**EQUITY**				
	(a) Equity Share Capital	2,825.63	2,637.21	2,825.63	2,637.21
	(b) Other Equity	1,53,951.98	1,47,699.51	42,534.09	56,502.76
	Total Equity	**1,56,777.61**	**1,50,336.72**	**45,359.72**	**59,139.97**
2	**LIABILITIES**				
	Non-current liabilities				
	Lease Liabilities	1,136.18	1,214.49	1,136.18	1,214.49
	Provision for Employee benefits	194.49	191.74	194.49	191.74
	Total non-current liabilities	**1,330.67**	**1,406.23**	**1,330.67**	**1,406.23**
	Current liabilities				
	Lease Liabilities	466.27	454.93	466.27	454.93
	(a) Financial Liabilities				
	II. Trade payables				
	a) To Micro & Small Enterprises	54.78	36.33	54.78	36.33
	b) Other than Micro & Small Enterprises	300.82	444.99	300.82	444.99
	III. Other Financial Liabilities	214.02	52.09	2,788.80	563.99
	(b) Provision Employee benefits	249.61	152.37	249.61	152.37
	(c) Other Current liabilities	91.56	222.59	91.56	222.59
	Total - Current liabilities	**1,377.06**	**1,363.30**	**3,951.84**	**1,875.20**
	Total Liabilities	**2,707.73**	**2,769.53**	**5,282.51**	**3,281.43**
	TOTAL - EQUITY AND LIABILITIES	**1,59,485.34**	**1,53,106.25**	**50,642.23**	**62,421.40**

SUVEN LIFE SCIENCES LTD. * HYDERABAD *

For Suven Life Sciences Ltd

Place : Hyderabad
Date : 05 November 2026

Venkat Jasti
Chairman & MD
DIN: 00278028

SUVEN LIFE SCIENCES LTD

Unaudited Standalone Cash flow statement

(Rs.In lakhs)

Particulars	For the half year ended September 30, 2026	For the half year ended September 30, 2025
A. Cash flow from operating activities		
Profit/(Loss) before tax	**(3,250.04)**	**(3,022.38)**
Adjustments :		
Depreciation and amortisation expense	445.74	268.52
ESOP expenses	220.96	53.73
Interest Income	(1,154.38)	(7.93)
Finance Cost	93.37	-
Interest on security deposit(116)	(4.67)	-
Foreign exchange loss/(profit)	12.08	-
Unrealised/sale of Gain on Current Investment	(266.76)	(425.56)
Operating profit before working capital changes	**(3,903.70)**	**(3,133.62)**
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(0.40)	26.87
Inventories	(0.43)	(0.30)
Other non current assets	(348.62)	(7.12)
Other current assets	363.21	(434.96)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(137.80)	(18.40)
Long term provisions	2.75	-
Short term provision	86.16	102.00
Other financial liabilities	161.93	136.08
Other current liabilities	(131.03)	8.12
Cash generated from operating activities	**(3,907.93)**	**(3,321.33)**
Income taxes paid (net of refunds)	131.03	18.42
Net Cash flows from operating activities	**(4,038.96)**	**(3,339.75)**
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(4,591.43)	(213.74)
Other financial assets	(1,025.59)	(94.11)
Interest received	1,154.37	7.93
Changes in Investments in Subsidiaries	(19,859.66)	(6,066.42)
Sale/(purchase) of mutual funds	16,962.14	(22,017.85)
Bank balances not considered as cash and cash equivalents	2,025.00	1,832.30
Net cash flow from /(used in) investing activities	**(5,335.17)**	**(26,551.89)**
C. Cash flows from financing activities		
Proceeds from Issue of Equity shares and related reserves	9,331.49	29,954.28
Proceeds from exercise of employee stock options	149.58	-
Lease payment	(223.47)	-
Net cash flow from /(used In) financing activities	**9,257.60**	**29,954.28**
Net increase/(decrease) in cash and cash equivalents	(116.53)	62.64
Cash and cash equivalents as at the beginning of the year	228.13	46.35
Cash and cash equivalents at the end of the year	**111.60**	**108.99**

For Suven Life Sciences Limited

SUVEN LIFE SCIENCES LTD. * HYDERABAD *

Place : Hyderabad
Date : 05 November 2026

Venkat Jasti
Chairman & MD
DIN: 00278028

SUVEN LIFE SCIENCES LTD

Unaudited Consolidated Cash flow statement

(Rs.In lakhs)

Particulars	For the half year ended September 30, 2026	For the half year ended September 30, 2025
A. Cash flow from operating activities		
Profit/(Loss) before tax	**(23,455.24)**	**(12,882.68)**
Adjustments :		
Depreciation and amortisation expense	445.74	268.52
ESOP expenses	220.96	53.73
Interest Income	(1,154.38)	(9.03)
Finance Cost	93.37	-
Interest on security deposit(116)	(4.67)	-
Foreign exchange loss/(profit)	12.08	-
Unrealised/sale of Gain on Current Investment	(266.76)	(425.56)
Operating profit before working capital changes	**(24,108.90)**	**(12,995.02)**
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	(0.40)	26.87
Inventories	(0.43)	(0.30)
Other non current assets	(348.62)	(7.12)
Other current assets	363.21	(434.96)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(137.80)	(18.40)
Long term provisions	2.75	-
Short term provision	86.16	102.00
Other financial liabilities	2,224.81	2,999.22
Other current liabilities	(131.03)	8.12
Cash generated from operating activities	**(22,050.25)**	**(10,319.59)**
Income taxes paid (net of refunds)	131.03	18.42
Net Cash flows from operating activities	**(22,181.28)**	**(10,338.01)**
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(4,591.43)	(213.74)
Other financial assets	(1,025.59)	(94.11)
Interest received	1,154.37	9.03
Sale/(purchase) of mutual funds	16,962.15	(22,017.86)
Foreign currency translation reserve	(15.95)	6.40
Bank balances not considered as cash and cash equivalents	2,025.00	2,152.38
Net cash flow from /(used in) investing activities	**14,508.55**	**(20,157.90)**
C. Cash flows from financing activities		
Proceeds from Issue of Equity shares and related reserves	9,331.49	29,954.28
Proceeds from exercise of employee stock options	149.58	
Changes In Lease Liability	(223.47)	-
Net cash flow from /(used In) financing activities	**9,257.60**	**29,954.28**
Net increase/(decrease) in cash and cash equivalents	1,584.87	(541.63)
Cash and cash equivalents as at the beginning of the year	827.91	1,502.55
Cash and cash equivalents at the end of the year	**2,412.78**	**960.92**

For Suven Life Sciences Limited

SUVEN LIFE SCIENCES LTD. HYDERABAD

Venkat Jasti
Chairman & MD
DIN: 00278028

Place : Hyderabad
Date : 05 November 2026

KARVY & CO
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED STANDALONE FINANCIAL RESULTS

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter and six months ended September 30, 2026 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended.

This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KARVY & CO
Chartered Accountants
(Firm Registration No.001757S)

KARVY & CO. Chartered Accountants Firm No: 001757S HYDERABAD

AJAYKUMAR KOSARAJU
Partner
M.No. 021989
UDIN: 26021989ZIWZSU1012

Place: Hyderabad
Date: 05-11-2026

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOLIDATED FINANCIAL RESULTS

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and six months ended September 30, 2026 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended", read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

   The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary
Suven Neuro Sciences Pte. Ltd.	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement. prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

KARVY & CO Chartered Accountants Firm No: 0017575 HYDERABAD

05-11-2026

6. We did not review the interim financial information of One (1) subsidiary included in the unaudited consolidated financial results, whose interim financial information reflects total assets of Rs. 2,295.08 Lakhs as at September 30, 2026, total revenues of Rs. -Nil-, and Rs. -Nil- for the quarter ended and six months period ended September 30, 2026 and total net loss after tax of Rs. (9,052.65) Lakhs and Rs. (20,201.76) Lakhs for the quarter ended and six months period ended September 30, 2026, and total comprehensive income of Rs. (9,070.51) Lakhs and Rs. (20,217.68) Lakhs for the quarter ended and six months period ended September 30, 2026, respectively, and net cash inflow of Rs.1,695.30 Lakhs for the six months' period ended September 30, 2026 as considered in the Statement. This interim financial information has been reviewed by another auditor whose report has been furnished to us by the Management, and our conclusion on the Statement, insofar as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor.

   The Statement also includes the interim financial information of One (1) subsidiary which has not been reviewed, whose interim financial information reflects total assets of Rs.6.10 Lakhs as at September 30, 2026, total revenues of Rs. -Nil-, and Rs. -Nil for the quarter ended and six months period ended September 30, 2026 and total net loss after tax of Rs.(3.43) lakhs and Rs.(3.43) Lakhs for the quarter ended and six months period ended September 30, 2026, and total comprehensive income of Rs.(3.46) Lakhs and Rs. (3.46) Lakhs for the quarter ended and six months period ended September 30, 2026, respectively, and net cash inflow of Rs.6.10 Lakhs for the six months ended September 30, 2026 as considered in the Statement. This interim financial information has not been audited/reviewed by its auditor and has been approved and furnished to us by the Management, and our conclusion on the Statement, insofar as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such unaudited interim financial information. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

   Our conclusion on the Statement is not modified in respect of the above matters.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)

KARVY & CO. Chartered Accountants Firm No: 001757S HYDERABAD

AJAYKUMAR KOSARAJU
Partner
M.No. 021989
UDIN: 26021989SMBLDJ8144

Place: Hyderabad
Date: 05-11-2026

Annexure 3

News Release

HYDERABAD, INDIA (5 Nov 2026) -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter and half year ended 30 Sep 2026. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 5 Nov 2026 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			6 months period ended		Year ended
	30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
Revenue	*79.33*	*110.89*	*46.97*	*190.22*	*71.64*	*210.45*
R&D and Operational expenses	1,121.15	1,360.68	806.90	2,481.83	1,333.05	2,916.17
Depreciation and Amortisation	23.02	21.55	13.17	44.57	26.85	56.14
Finance cost	4.58	4.76	-	9.34	-	1.58
Total expenses	*1,148.75*	*1,387.00*	*820.07*	*2,535.75*	*1,359.91*	*2,973.89*
Exceptional items (insurance claim received)	-	-	-	-	-	-
Tax	-	-	-	-	-	-
Profit/(Loss) After Tax for the period/year	*(1,069.42)*	*(1,276.10)*	*(773.10)*	*(2,345.52)*	*(1,288.27)*	*(2,763.44)*
Other comprehensive income	(2.34)	(0.36)	0.85	(2.70)	0.34	(11.84)
Total comprehensive income	*(1,071.77)*	*(1,276.46)*	*(772.25)*	*(2,348.23)*	*(1,287.93)*	*(2,775.28)*
Paid up equity capital	282.56	263.99	227.47	282.56	227.47	263.72
Earnings per share of Rs.1 each (EPS)	*(3.77)*	*(4.84)*	*(3.48)*	*(8.61)*	*(5.80)*	*(12.13)*

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Completed enrollment milestone in Global Phase 3 Trial for Agitation in Alzheimer's Dementia. The last patient last visit will be in quarter 1, 2027 calendar year enabling progression towards database lock and reporting of topline data potentially in Q2 - 2027 calendar year.
- SUVN-G3031 (Samelisant) – Global Phase-3 clinical study to confirm efficacy and safety of Samelisant in narcolepsy is in progress.
- SUVN-911 (Ropanicant) – Phase 2B clinical study in USA is completed with successful outcome. Targeting for Global Phase -3 program initiation during Q2-2027 calendar year.
- SUVN-D4010 (Usmarapride) – Phase-2 Proof of Concept (PoC) Study for Cognitive Dysfunction initiated during October 2026.
- SUVN-I6107 – Phase 1 study for establishing safety and pharmacokinetics completed and Phase 2 enabling toxicological studies are underway.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued in growth of revenue that may make our products/services offerings less competitive.